ATE414508T1 - Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol - Google Patents

Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol

Info

Publication number
ATE414508T1
ATE414508T1 AT04725895T AT04725895T ATE414508T1 AT E414508 T1 ATE414508 T1 AT E414508T1 AT 04725895 T AT04725895 T AT 04725895T AT 04725895 T AT04725895 T AT 04725895T AT E414508 T1 ATE414508 T1 AT E414508T1
Authority
AT
Austria
Prior art keywords
dosh
receptor agonist
sugar alcohol
solid pharmaceutical
forms containing
Prior art date
Application number
AT04725895T
Other languages
German (de)
English (en)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Pharma Gmbh
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE414508(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh, Mitsubishi Pharma Corp filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE414508T1 publication Critical patent/ATE414508T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT04725895T 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol ATE414508T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
ATE414508T1 true ATE414508T1 (de) 2008-12-15

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04725895T ATE414508T1 (de) 2003-04-08 2004-04-06 Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
ATA606/2004A AT501681B1 (de) 2003-04-08 2004-04-06 Feste orale pharmazeutische zusammensetzung enthaltend 2-amino-1,3-propandiole
AT0074408A AT504853A2 (de) 2003-04-08 2008-05-08 Organische verbindungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
ATA606/2004A AT501681B1 (de) 2003-04-08 2004-04-06 Feste orale pharmazeutische zusammensetzung enthaltend 2-amino-1,3-propandiole
AT0074408A AT504853A2 (de) 2003-04-08 2008-05-08 Organische verbindungen

Country Status (41)

Country Link
US (11) US20060275357A1 (enEXAMPLES)
EP (5) EP2319502A1 (enEXAMPLES)
JP (3) JP5495467B2 (enEXAMPLES)
KR (3) KR20050121712A (enEXAMPLES)
CN (2) CN101797241B (enEXAMPLES)
AR (3) AR043987A1 (enEXAMPLES)
AT (3) ATE414508T1 (enEXAMPLES)
AU (1) AU2004228929B2 (enEXAMPLES)
BE (2) BE1015972A5 (enEXAMPLES)
BR (1) BRPI0409250B8 (enEXAMPLES)
CA (2) CA2521325C (enEXAMPLES)
CL (2) CL2004000745A1 (enEXAMPLES)
CY (3) CY1110260T1 (enEXAMPLES)
DE (4) DE602004017847D1 (enEXAMPLES)
DK (2) DK1613288T3 (enEXAMPLES)
EC (1) ECSP056090A (enEXAMPLES)
ES (3) ES2228282B1 (enEXAMPLES)
FR (2) FR2854073B1 (enEXAMPLES)
GB (1) GB2400318B (enEXAMPLES)
GR (1) GR1005052B (enEXAMPLES)
HR (3) HRP20050886B1 (enEXAMPLES)
HU (2) HUE028247T2 (enEXAMPLES)
IL (3) IL170888A (enEXAMPLES)
IS (2) IS2682B (enEXAMPLES)
IT (1) ITMI20040682A1 (enEXAMPLES)
LU (1) LU91867I2 (enEXAMPLES)
MA (1) MA27729A1 (enEXAMPLES)
MX (1) MXPA05010860A (enEXAMPLES)
MY (1) MY141249A (enEXAMPLES)
NO (4) NO329332B1 (enEXAMPLES)
NZ (3) NZ592339A (enEXAMPLES)
PE (5) PE20050396A1 (enEXAMPLES)
PL (2) PL1613288T3 (enEXAMPLES)
PT (1) PT1613288E (enEXAMPLES)
RU (5) RU2358716C2 (enEXAMPLES)
SG (1) SG175449A1 (enEXAMPLES)
SI (2) SI1613288T1 (enEXAMPLES)
TN (1) TNSN05256A1 (enEXAMPLES)
TW (1) TWI332847B (enEXAMPLES)
WO (1) WO2004089341A1 (enEXAMPLES)
ZA (1) ZA200507394B (enEXAMPLES)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993115B (zh) * 2004-07-30 2011-12-28 诺瓦提斯公司 2-氨基-1,3-丙二醇化合物的制剂
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
SG165364A1 (en) * 2005-09-09 2010-10-28 Novartis Ag Treatment of autoimmune diseases
ES2628620T3 (es) 2005-11-09 2017-08-03 Onyx Therapeutics, Inc. Compuesto para inhibición de enzimas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PT2041158E (pt) 2006-06-19 2013-07-17 Onyx Therapeutics Inc Péptido epoxicetonas para inibição de proteassoma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP2086514A2 (en) * 2006-09-26 2009-08-12 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
MX2009010474A (es) 2007-03-29 2009-10-19 Daiichi Sankyo Co Ltd Composicion farmaceutica.
MY173938A (en) 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP2209493A2 (en) * 2007-10-12 2010-07-28 Novartis AG Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
WO2009152922A1 (de) * 2008-06-20 2009-12-23 Merck Patent Gmbh Direkt verpressbare und schnell zerfallende tablettenmatirx
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
PL2334202T3 (pl) * 2008-09-04 2012-04-30 Cargill Inc Tabletkowanie erytrytolu
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
US8680146B2 (en) 2008-11-11 2014-03-25 Novartis Ag Organic compounds
EP2356090B1 (en) * 2008-11-11 2017-07-05 Novartis AG Crystalline forms of fingolimod hcl
CA2747427C (en) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Method for producing diamine derivative
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
JP5666424B2 (ja) 2009-03-10 2015-02-12 第一三共株式会社 ジアミン誘導体の製造方法
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
TW201102064A (en) * 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR101708528B1 (ko) 2010-03-19 2017-02-20 다이이찌 산쿄 가부시키가이샤 디아민 유도체의 결정 및 그 제조 방법
ES2601884T3 (es) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedimiento para mejorar la capacidad de disolución de un anticoagulante
CA2797029A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
WO2012002538A1 (ja) 2010-07-02 2012-01-05 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMOD POLYMORPHES AND METHOD THEREFOR
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
PT2665471T (pt) 2011-01-19 2018-03-21 Pathologica Llc Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
JO3177B1 (ar) * 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
EP2742941B1 (en) 2011-08-10 2018-04-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN105163730B (zh) 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
WO2015015254A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107530301A (zh) * 2015-01-20 2018-01-02 汉达医药有限责任公司 稳定的固体芬戈莫德剂型
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
EP4438037A1 (en) * 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
ES2230571T3 (es) 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4153563B2 (ja) * 1997-02-27 2008-09-24 ノバルティス アーゲー 医薬組成物
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
HUP0301688A3 (en) 2000-07-13 2006-05-29 Sankyo Co Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them
JP2004507552A (ja) * 2000-08-31 2004-03-11 メルク　エンド　カムパニー　インコーポレーテッド 免疫調節剤としてのリン酸誘導体
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
JP4012823B2 (ja) 2001-03-26 2007-11-21 ノバルティス アクチエンゲゼルシャフト ２−アミノ−誘導体
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
PT1431284E (pt) 2001-09-27 2008-01-21 Kyorin Seiyaku Kk Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
CA2472713C (en) 2002-01-18 2011-07-19 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法

Also Published As

Publication number Publication date
PE20130200A1 (es) 2013-03-09
EP1613288B1 (en) 2008-11-19
NZ586280A (en) 2011-12-22
WO2004089341A1 (en) 2004-10-21
IS8114A (is) 2005-11-01
PE20090743A1 (es) 2009-07-17
GR1005052B (el) 2005-11-30
DE122011100047I1 (de) 2011-12-15
JP2011006461A (ja) 2011-01-13
AT501681A1 (de) 2006-10-15
PL1613288T3 (pl) 2009-07-31
CA2521325A1 (en) 2004-10-21
EP2008650A3 (en) 2011-04-27
ES2228282B1 (es) 2006-02-16
HRP20050886B1 (en) 2011-01-31
EP2769713A1 (en) 2014-08-27
ES2556947T3 (es) 2016-01-21
EP2319502A1 (en) 2011-05-11
US20090203798A1 (en) 2009-08-13
US20190175527A1 (en) 2019-06-13
CY2011013I2 (el) 2014-04-09
CY1117071T1 (el) 2017-04-05
US20220031609A1 (en) 2022-02-03
RU2475236C2 (ru) 2013-02-20
KR20120101148A (ko) 2012-09-12
HUE028247T2 (en) 2016-12-28
ZA200507394B (en) 2007-03-28
PT1613288E (pt) 2009-02-25
TW200503784A (en) 2005-02-01
HK1071685A1 (en) 2005-07-29
BRPI0409250B1 (pt) 2017-07-11
JP2013177404A (ja) 2013-09-09
FR2854073B1 (fr) 2008-03-14
BRPI0409250A (pt) 2006-03-28
RU2005134173A (ru) 2006-09-10
IL197578A0 (en) 2011-07-31
SG175449A1 (en) 2011-11-28
AT504853A2 (de) 2008-08-15
RU2009105403A (ru) 2010-08-27
NO335120B1 (no) 2014-09-22
EP1613288A1 (en) 2006-01-11
CA2707750A1 (en) 2004-10-21
US8324283B2 (en) 2012-12-04
LU91867I9 (enEXAMPLES) 2019-01-03
AU2004228929A1 (en) 2004-10-21
DE202004021680U1 (de) 2010-04-22
ECSP056090A (es) 2006-03-01
IL170888A (en) 2010-06-16
HK1091114A1 (en) 2007-01-12
US20140011885A1 (en) 2014-01-09
AR043987A1 (es) 2005-08-17
RU2010147000A (ru) 2012-08-10
FR11C0036I2 (fr) 2023-12-29
RU2475237C2 (ru) 2013-02-20
NO2011016I1 (no) 2011-09-19
MXPA05010860A (es) 2006-05-25
DK1613288T3 (da) 2009-03-23
CN101797241A (zh) 2010-08-11
RU2358716C2 (ru) 2009-06-20
KR20050121712A (ko) 2005-12-27
IS8885A (is) 2010-02-25
CN1767819A (zh) 2006-05-03
US20060275357A1 (en) 2006-12-07
EP2008650A2 (en) 2008-12-31
AR078781A2 (es) 2011-11-30
NO20131287L (no) 2006-01-09
NO329332B1 (no) 2010-09-27
IE20040246A1 (en) 2004-12-15
NZ542622A (en) 2009-01-31
US20080311188A1 (en) 2008-12-18
CY2011013I1 (el) 2014-04-09
US20170290787A1 (en) 2017-10-12
GB2400318A (en) 2004-10-13
AT501681B1 (de) 2012-04-15
JP5543298B2 (ja) 2014-07-09
EP2316431A1 (en) 2011-05-04
CL2004000745A1 (es) 2005-02-11
SI1613288T1 (sl) 2009-04-30
GB2400318B (en) 2005-08-10
NO2011016I2 (no) 2012-08-27
AU2004228929B2 (en) 2008-02-07
PE20150676A1 (es) 2015-05-17
PE20050396A1 (es) 2005-07-05
BRPI0409250B8 (pt) 2022-01-18
NO20100250L (no) 2006-01-09
FR11C0036I1 (fr) 2011-10-14
DE602004017847D1 (de) 2009-01-02
HUS1100016I1 (hu) 2016-08-29
KR101367574B1 (ko) 2014-02-25
US20110105620A1 (en) 2011-05-05
NO334116B1 (no) 2013-12-16
IL197578A (en) 2015-10-29
LU91867I2 (fr) 2011-11-08
CA2521325C (en) 2010-09-14
IS2682B (is) 2010-10-15
DE102004016947A1 (de) 2004-10-21
US20140255497A1 (en) 2014-09-11
MA27729A1 (fr) 2006-01-02
ES2228282A1 (es) 2005-04-01
JP2004307506A (ja) 2004-11-04
DK2316431T3 (en) 2016-01-11
CY1110260T1 (el) 2014-04-09
JP5495467B2 (ja) 2014-05-21
RU2012148593A (ru) 2014-05-20
GB0407819D0 (en) 2004-05-12
GR20040100121A (el) 2004-12-17
FR2854073A1 (fr) 2004-10-29
SI2316431T1 (sl) 2016-04-29
ES2320767T3 (es) 2009-05-28
ITMI20040682A1 (it) 2004-07-06
BE2011C030I2 (enEXAMPLES) 2023-03-07
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
AR078782A2 (es) 2011-11-30
US20200237690A1 (en) 2020-07-30
HRP20100601A2 (hr) 2011-03-31
NO20055231D0 (no) 2005-11-07
US20130108675A1 (en) 2013-05-02
RU2010146697A (ru) 2012-05-27
CN101797241B (zh) 2013-03-27
KR20110005320A (ko) 2011-01-17
PE20131352A1 (es) 2013-11-14
HRP20100601B1 (hr) 2016-12-02
TNSN05256A1 (en) 2007-07-10
HRP20100600A2 (hr) 2011-03-31
CN1767819B (zh) 2010-07-28
HRP20050886A2 (en) 2006-11-30
TWI332847B (en) 2010-11-11
MY141249A (en) 2010-03-31
HK1155647A1 (en) 2012-05-25
EP2316431B1 (en) 2015-09-30
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
IL242037A0 (en) 2015-11-30
NZ592339A (en) 2012-09-28

Similar Documents

Publication Publication Date Title
ATE414508T1 (de) Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
DE602006010088D1 (de) Pharmazeutische formulierungen mit einem langzeit-beta-2-agonisten zur verabreichung durch verneblung
ZA200602260B (en) A pharmaceutical composition comprising a P2X7 receptor antagonist and a nonsteroidal anti-inflammatory drug
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
ATE418984T1 (de) Pharmazeutische formulierungen mit einem antibiotikum, einem triazol und einem kortikosteroid
DE602004025950D1 (de) Pharmazeutische formulierung mit lanthanum-verbindungen
ATE444070T1 (de) Manipulationssichere orale pharmazeutische dosierformen enthaltend ein opiatanalgetikum
DE60111265D1 (de) Pharmazeutische zusammensetzungen mit nmda-rezeptor-agonist
EP1477403A4 (en) MEDICINES SUPPLY
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
ATE362771T1 (de) Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ATE332690T1 (de) Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ATE373488T1 (de) Antimykobakterielle pharmazeutische zusammensetzung mit einem arzneimittel gegen tuberkulose
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
ITMI20020921A0 (it) Dispositivo per la sommistrazione di farmaci
ATE428416T1 (de) Feste pharmazeutische zubereitung enthaltend (r)- (-)-2-ä5-(4-fluorophenyl)-3- pyridylmethylaminomethylü-chroman
HK1071685B (en) Pharmaceutical composition comprising an s1p receptor agonist
HK1089362A (en) A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug
DE602004030921D1 (de) Pharmazeutische zusammensetzung
ES1055546Y (es) Contenedor-dosificador para pastillas farmaceuticas.
ITMI20020232A1 (it) Dispositivo per iniettare materiali riempitivi